证券时报·数据宝统计显示，以发行日期为基准统计，截至12月15日，今年以来科创板累计有17家公司 发行新股，累计募资金额达350.89亿元，单家公司平均募集资金20.64亿元。分区间来看，募资金额超10 亿元的有12家，募资金额5亿元至10亿元的有4家，募资金额在5亿元以下的有1家。 摩尔线程为今年以来募资金额最多的科创板公司，首发募集资金达80.00亿元，募资主要投向使用部分 闲置募集资金进行现金管理，摩尔线程新一代自主可控AI训推一体芯片研发项目，摩尔线程新一代自 主可控图形芯片研发项目等；其次是西安奕材，募资金额为46.36亿元，募资主要用于西安奕斯伟硅产 业基地二期项目，使用部分募集资金进行现金管理等。募资金额较多的还有沐曦股份、禾元生物、屹唐 股份等，分别募资41.97亿元、25.99亿元、24.97亿元。 发行价格方面，今年已发行的科创板股平均首发价格为36.56元，发行价在50元以上的有4家，其中，发 行价超百元的有2家，发行价最高的是摩尔线程，发行价为114.28元，沐曦股份、昂瑞微次之，发行价 分别为104.66元、83.06元，发行价较低的有屹唐股份、西安奕材等，首发价格分别为8.45元、 ...

证券日报网讯12月9日，必贝特在互动平台回答投资者提问时表示，目前，公司在研产品管线中，暂无 专门针对流感病毒的特效药物。 ...

格隆汇12月9日丨必贝特(688759.SH)在互动平台表示，目前，我司在研产品管线中，暂无专门针对流感 病毒的特效药物。 ...

证券代码：688759 证券简称：必贝特 公告编号：2025-008 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 广州必贝特医药股份有限公司 2025年第一次临时股东大会决议公告 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 28 日 （二） 股东大会召开的地点：广州市黄埔区科学城崖鹰石路 3 号 8 层会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 620 | | --- | --- | | 普通股股东人数 | 620 | | 2、出席会议的股东所持有的表决权数量 | 254,484,924 | | 普通股股东所持有表决权数量 | 254,484,924 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 56.5475 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 56.5475 | ...

湖南启元律师事务所 关于广州必贝特医药股份有限公司 2025年第一次临时股东大会的 法律意见书 2025年11月 致：广州必贝特医药股份有限公司 湖南启元律师事务所（以下简称"本所"）接受广州必贝特医药股份有限公司 （以下简称"公司"）的委托，指派本所律师出席了公司 2025 年第一次临时股东 大会（以下简称"本次股东大会"），对本次股东大会的召集和召开程序、出席会 议人员及召集人的资格、表决程序和表决结果的合法有效性进行现场律师见证， 并发表本法律意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简 称"《股东会规则》"）等我国现行法律、法规、规范性文件以及《广州必贝特医 药股份有限公司公司章程》（以下简称"《公司章程》"）等有关规定出具本法律 意见书。 本所及本所律师声明如下： （一）本所律师根据本法律意见书出具日以前已经发生或者存在的事实，严 格履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证， 保证本法律意见书所认定的事实真实、准确、完整，所发表的结论性意见合法、 准确，不存在虚假 ...

Market Overview - The chemical pharmaceutical sector increased by 0.02% on November 28, with Yifang Bio leading the gains [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] Top Gainers in Chemical Pharmaceutical Sector - Yifang Bio (688382) closed at 29.48, up 5.93% with a trading volume of 206,700 shares and a transaction value of 590 million [1] - Bibet (688759) closed at 34.88, up 5.47% with a trading volume of 115,300 shares [1] - Weier Pharmaceutical (603351) closed at 28.83, up 5.45% with a trading volume of 19,400 shares and a transaction value of 54.88 million [1] - Other notable gainers include Tingjian (002653) up 4.43% and Dongcheng Pharmaceutical (002675) up 3.53% [1] Top Losers in Chemical Pharmaceutical Sector - Guangji Pharmaceutical (000952) saw a significant decline of 9.98%, closing at 9.38 with a trading volume of 1,153,700 shares [2] - New Ganjing (920367) decreased by 5.73%, closing at 21.57 with a trading volume of 37,700 shares [2] - Hendi Pharmaceutical (301211) fell by 5.24%, closing at 15.19 with a trading volume of 310,700 shares [2] - Other notable losers include Beida Pharmaceutical (000788) down 3.80% and Fuyuan Pharmaceutical (6801089) down 3.71% [2] Fund Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 599 million from institutional investors, while retail investors saw a net inflow of 377 million [2] - Notable net inflows from retail investors were observed in stocks like Yifang Bio and Bibet, despite overall net outflows from institutional and speculative funds [3] Individual Stock Fund Flow - Yifang Bio had a net inflow of 57.86 million from institutional investors, but a net outflow from speculative and retail investors [3] - Huadong Pharmaceutical (000963) also saw a significant net inflow of 56.40 million from institutional investors, with outflows from speculative and retail investors [3] - Other stocks like Bibet and Dongcheng Pharmaceutical showed mixed fund flows, indicating varied investor sentiment [3]

Core Points - On November 27, Bibete's stock rose by 2.57% with a trading volume of 426 million yuan [1] - The financing data indicates that Bibete had a financing buy amount of 34.91 million yuan and a financing repayment of 45.09 million yuan, resulting in a net financing buy of -10.18 million yuan [1] - As of November 27, the total balance of margin trading for Bibete was 91.90 million yuan, which accounts for 5.98% of its market capitalization [1] Financing Summary - On the same day, Bibete's financing buy was 34.91 million yuan, while the current financing balance stands at 91.90 million yuan [1] - The financing balance represents 5.98% of the company's circulating market value [1] Securities Lending Summary - On November 27, Bibete had no shares repaid or sold in the securities lending market, resulting in a sell amount of 0.00 yuan [1] - The securities lending balance and remaining shares were both recorded at 0.00 [1] Company Overview - Bibete Pharmaceutical Co., Ltd. is located in the Science City of Guangzhou, Guangdong Province, and was established on January 19, 2012, with a listing date set for October 28, 2025 [1] - The company focuses on the independent research and development of innovative drugs [1] Shareholder Information - As of November 10, Bibete had 24,000 shareholders, a decrease of 50.05% from the previous period [1] - The average number of circulating shares per shareholder increased by 100.21% to 1,938 shares [1] Financial Performance - For the period from January to September 2025, Bibete reported an operating income of 0.00 yuan and a net profit attributable to the parent company of -107 million yuan [1]

Group 1 - The closing price of Bibet-U (688759) on November 26 was 32.24 yuan, with a rise of 9.07% and a turnover rate of 31.05% [2] - The stock was listed on the daily trading list due to its turnover rate exceeding 30% [2] - The total trading volume for the day was 466 million yuan, with a price fluctuation of 13.87% [2] Group 2 - The top five trading departments accounted for a total transaction amount of 110 million yuan, with a net buying amount of 33.39 million yuan [2] - Among the top five buying departments, two were institutional special seats, with buying amounts of 11.54 million yuan and 11.48 million yuan respectively [2] - The leading selling department was Guotai Junan Securities Co., Ltd. Fuzhou Yangqiao East Road Securities Business Department, with a selling amount of 9.41 million yuan [2] Group 3 - The net inflow of main funds for the stock was 58.31 million yuan for the day [3] - The top buying departments included Guotai Junan Securities Headquarters with 18.76 million yuan and Goldman Sachs (China) Securities with 16.97 million yuan [3] - The top selling departments included Guotai Junan Securities Fuzhou Yangqiao East Road with 9.41 million yuan and Guotai Junan Securities Headquarters with 8.88 million yuan [3]

Core Viewpoint - The chemical pharmaceutical sector experienced a rise of 1.66% on November 26, with Frontier Biotech leading the gains, while the overall Shanghai Composite Index fell by 0.15% [1]. Group 1: Stock Performance - Frontier Biotech (688221) closed at 20.20, up 12.85% with a trading volume of 455,500 shares and a transaction value of 916 million yuan [1]. - Yuyuan Pharmaceutical (688658) closed at 26.88, up 12.00% with a trading volume of 218,600 shares and a transaction value of 577 million yuan [1]. - Fuyuan Pharmaceutical (6801089) closed at 24.53, up 10.00% with a trading volume of 113,800 shares and a transaction value of 274 million yuan [1]. - Other notable performers include Guangji Pharmaceutical (000952) with a 9.99% increase and Beida Pharmaceutical (000788) with a 9.94% increase [1]. Group 2: Fund Flow Analysis - The chemical pharmaceutical sector saw a net inflow of 43.08 million yuan from institutional investors, while retail investors contributed a net inflow of 23.8 million yuan [2]. - The sector experienced a net outflow of 281 million yuan from speculative funds [2]. - Key stocks with significant fund flows include Heng Rui Pharmaceutical (600276) with a net inflow of 231 million yuan from institutional investors [3]. Group 3: Individual Stock Fund Flow - New China Pharmaceutical (000756) had a net inflow of 68.2 million yuan from institutional investors, while experiencing a net outflow of 21.7 million yuan from speculative funds [3]. - Fuyuan Pharmaceutical (601089) saw a net inflow of 67.6 million yuan from institutional investors, with a net outflow of 39.4 million yuan from speculative funds [3]. - Other stocks like Beibete (688759) and Yuyuan Pharmaceutical (688658) also showed varying levels of net inflows and outflows from different investor categories [3].

证券代码：688759 证券简称：必贝特 公告编号：2025-007 广州必贝特医药股份有限公司 关于开立募集资金现金管理专用结算账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 途。 二、风险控制措施 1、公司将严格按照《上海证券交易所科创板上市公司自律监管指引第1 号——规范运作》《上市公司募集资金监管规则》等有关规定办理相关现金管理 业务。 广州必贝特医药股份有限公司（以下简称"公司"）于2025年11月11日分别 召开了第二届董事会审计委员会2025年第五次会议、第二届董事会第七次（临 时）会议、第二届监事会第七次（临时）会议，审议通过了《关于使用部分暂 时闲置募集资金进行现金管理的议案》，同意公司及公司子公司使用额度不超过 人民币9.00亿元（含本数）的暂时闲置募集资金进行现金管理，用于购买安全 性高、流动性好、满足保本需求的理财产品或存款类产品。具体内容详见公司 于2025年11月13日在上海证券交易所网站（www.sse.com.cn）上披露的《关于使 用部分暂时闲置募集资金进行现金管理的公告》（公 ...